Search Results 241-250 of 22996 for Phase
About this study. This is a Phase III, randomised, open-label, sponsor-blinded, 3-arm, multicentre, global study assessing the efficacy and safety of ...
A Phase 1 Dose Escalation and Expansion Study of TGR-1202 + Ruxolitinib in Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (PPV-MF), ...
Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272) · Share ...
The primary objective of the study is to evaluate the efficacy of monthly doses of aducanumab in slowing cognitive and functional impairment as measured by ...
The purpose of this study is to determine the safety and efficacy of brepocitinib (a tyrosine kinase [TYK]2/Janus kinase [JAK]1 inhibitor) in adult participants ...
About this study. To determine the antitumor activity of tipifarnib in patients with locally advanced unresectable or metastatic, relapsed and/or refractory ...
Clinical Trials · A Phase 3, randomized, open-label, controlled study comparing the efficacy and safety of zanidatamab to trastuzumab, each in combination with ...
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC).
Study to evaluate the safety, tolerability, and pharmacokinetics of TAS-102 in patients with advanced solid tumors and varying degrees of hepatic impairment.
This is a phase 2, multicenter, open-label study in patients with Newly Diagnosed Multiple Myeloma (NDMM) who have not received prior systemic treatment for ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your gift to celebrate this day advances our doctors’ lifesaving work.